Alpha Tau Medical Ltd (DRTS) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2023 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Alpha Tau Medical Ltd  (NASDAQ: DRTS)


Alpha Tau Medical Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Alpha Tau Medical Ltd's ROA in the fourth quarter of 2025?
Alpha Tau Medical Ltd achieved a return on average assets (ROA) of 41.24 % in its fourth quarter of 2025, this is above DRTS's average return on assets of 14.69%.
Alpha Tau Medical Ltd assets over the 12 months ending in its fourth quarter of 2025 are valued at $103 million

ROA has improved compared to 30.88% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 29 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 114.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Total Assets Change 51.26 % 11.81 % 24.37 % -0.59 % -33.94 %
Y / Y Net Income Change 46.2 % - - - -13.64 %
Net Income (TTM) in million 43 29 29 29 29
Return On Assets (TTM) 41.24 % 30.88 % 31.75 % 33.75 % 33.7 %
DRTS's Total Ranking # 114 # # # # 4600
Total Assets (TTM) in million 106 98 111 98 70
Seq. Total Assets Change 7.33 % -11.28 % 12.71 % 40.94 % -20.66 %
Seq. Net Income Change - - - - -

DRTS's 5 Years Annual ROA >> Back to DRTS Management Effectiveness >> Compare DRTS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 7
Sector # 30
Overall # 110

Return On Assets Statistics
High Average Low
40.35 %
14.69 %
-36.83 %
(Dec 31 2025)   (Dec 31 2024)



  News about Alpha Tau Medical Ltd Return on Assets ROA

Initial Treatment Success in Alpha Taus Clinical Trials for Pancreatic Cancer Amid Financial Concerns

Alpha Tau Medical Ltd. has recently marked a milestone in cancer therapeutics by successfully treating its first patient in a multi-center clinical trial focused on pancreatic cancer, utilizing its novel alpha radiation therapy, DaRT (Diffusing Alpha-emitters Radiation Therapy). This development comes at a time when the company faces financial scrutiny, particularly regarding its return on assets (ROA), which shows a decline relative to previous quarters and peers. Clinical Trial Overview The initiation of the multi-center pilot study for Alpha DaRT is a significant step forward in the fight against pancreatic cancer, a notoriously aggressive and often fatal disease. Traditional treatments have been limited in efficacy, leading to a pressing need for innovative therapeutic options. Alpha DaRT employs a unique mechanism, delivering alpha particles directly to tumors, potentially leading to more localized and effective targeting of cancer cells while sparing surrounding healthy tissue.



Financial Statements
Alpha Tau Medical Ltd's Assets $ 106 million DRTS's Balance sheet
Alpha Tau Medical Ltd's Income $ 43 million Quarterly DRTS's Income Statement
DRTS's Income by Division See DRTS's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 24.52 % -13.71 % -21.14 % 164.49 % -
Total Assets in million 96 77 89 113 43
Y / Y Net Income Change - - -13.64 % 23.8 % -
Net Income in million 43 -32 29 34 27
Annual Return On Assets 44.47 % -41.24 % 32.68 % 29.84 % 63.76 %

DRTS's 5 Years Annual ROA >> Back to DRTS Management Effectiveness >> Compare DRTS ROA to its Competitors



Comment on DRTS's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 44.47 % compared to prior year, due to annual net income growth of % to $42.63 million, while value of Alpha Tau Medical Ltd's overall assets grew just by 24.52 % to $95.86 million, compared to $95.86 a year before.


More Return On Assets Ratios
DRTS's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DRTS's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DRTS's Competitors
Subscribers only: Roa for Alpha Tau Medical Ltd's Suppliers
Subscribers only: Return On Assets for DRTS's Customers

You may also want to know
DRTS's Roi DRTS's Inventory Turnover Ratio DRTS's Growth Rates DRTS's Dividend Comparisons
DRTS's Profitability Ratios DRTS's Asset Turnover Ratio DRTS's Dividend Growth
DRTS's Roe DRTS's Valuation Ratios DRTS's Financial Strength Ratios DRTS's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Icecure Medical Ltd  108.42 %
Atara Biotherapeutics Inc   87.55 %
Traws Pharma inc   86.12 %
Sanuwave Health Inc   65.98 %
Exelixis Inc   61.66 %
Entera Bio Ltd   61.28 %
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %

Date modified: 2026-07-07T10:26:37+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.